Adial Pharmaceuticals Files Post-Effective Amendments to Registration Statements For Outstanding Shares Underlying Existing Warrants and Shelf Registration Statement to Provide Financial Flexibility Apr 23, 2020
Adial Pharmaceuticals Verifies Proprietary Genetic Test in Landmark ONWARD™ Pivotal Phase 3 Clinical Trial Apr 16, 2020
Adial Pharmaceuticals Issued Second Patent Covering AD04 as a Treatment for Opioid Use Disorder Apr 15, 2020
Adial Pharmaceuticals Receives Issue Notification for Patent Covering AD04 for the Treatment of Opioid Use Disorder Mar 26, 2020
Adial Pharmaceuticals Announces Modifications to the Phase 3 Pivotal Trial of AD04 to Protect Subjects from COVID-19 Mar 17, 2020
Adial Pharmaceuticals CEO Selected as a Luncheon Keynote Speaker for the 2020 Wall Street Conference and Retreat Feb 14, 2020
